i-Pharm GxP

Support that goes beyond. That’s what truly sets a great recruiter apart. And it’s exactly what clients experience when they work with Hamish Corson, our Senior Business Manager. From the first conversation to advice well after placement, Hamish makes sure every candidate feels guided, supported, and confident at every step. Here’s what Holly Brunbeck, Senior Process Design Lead at Eli Lilly and Company, had to say. 💬 Looking for a recruitment partner who genuinely invests in your journey? 📌 Connect with Hamish: https://lnkd.in/ejFpDt2r #iPharmGxP #Testimonial #Recruitment

On May 26, we honoured Memorial Day, a time to remember the brave individuals who gave their lives in service to our country. We reflected on their sacrifice and expressed our deepest gratitude to the heroes who made the ultimate commitment. Know someone whose legacy should be remembered? Share their name and story below. #iPharmGxP #MemorialDay #LifeSciences

On May 26, we honoured Memorial Day, a time to remember the brave individuals who gave their lives in service to our country. We reflected on their sacrifice and expressed our deepest gratitude to the heroes who made the ultimate commitment. Know someone whose legacy should be remembered? Share their name and story below. #iPharmGxP #MemorialDay #LifeSciences

The Cell and Gene Therapy Catapult has released updated guidance on authorisation procedures for GMO containing clinical trial products in the UK. It breaks down timelines, submission routes, and which agencies you’ll need to engage with, essential for anyone navigating approvals under contained use or deliberate release frameworks. Clearer definitions. Practical timelines. Smarter planning. This update could help reduce approval delays and improve sponsor confidence. In light of this new guidance, we’re curious to know: Where do you see the biggest challenge in GMO trial approvals? Vote in the poll and share your thoughts in the comments. #iPharmGxP #CellAndGeneTherapy

Know someone exploring their next role in Life Sciences? Refer a friend, colleague or former coworker and earn up to $2,000 in vouchers when they’re successfully placed! To submit a referral, send the candidate’s CV and contact details to: 📧 Harry Reeve – https://lnkd.in/ec577ec9 📧 Hamish Corson – https://lnkd.in/ejFpDt2r We're always looking to connect with professionals across biologics, cell and gene therapy, and sterile manufacturing. #Referral #iPharmGxP #LifeSciences #CareersInScience #BiotechJobs #PharmaJobs

Big moves from Eli Lilly and another step forward for innovation in chronic disease management. In a recent Phase 3 trial, Lilly’s orforglipron, a once-daily, oral GLP-1 receptor agonist, matched the efficacy of injectable semaglutide (Ozempic) in reducing both blood sugar and weight in people with type 2 diabetes. The trial spanned over 660 adults, and those receiving orforglipron saw significant A1C reductions and up to 9.4% weight loss, marking a potential shift in how GLP-1 therapies are administered. How do you think this could shape the future of diabetes care and healthcare delivery more broadly? Share your thoughts in the comments. #iPharmGxP #DiabetesCare #EliLilly #GLP1 #BiotechNews #ClinicalTrials #MetabolicHealth

From May 6–12, we celebrate National Nurses Week, recognising the dedication, compassion, and expertise of nurses across the world. Happy National Nurses Week to the brilliant nurses leading from the frontlines and behind the scenes. Know a nurse who deserves a shoutout? Tag them and say thank you below. #iPharmGxP #NationalNursesWeek #LifeSciences #ClinicalResearch #HealthcareLeadership  

Today marks Cinco de Mayo, a celebration of heritage, resilience, and cultural pride. In life sciences, we’re reminded that global innovation depends on diverse perspectives and inclusive collaboration. Progress happens when we bring people together across borders, backgrounds, and cultures. Feliz Cinco de Mayo from all of us at i-Pharm GxP. P.S. Are you team tacos 🌮 or tamales this year? Let us know in the comments! #iPharmGxP #CincoDeMayo #DiversityInSTEM #LifeSciences #GlobalInnovation

If you’re looking for experienced writers who understand both the science and the regulatory expectations of Medical Writing/Technical Writing, we provide professionals qualified to deliver across every stage of the development process. Our technical capabilities cover: → SOPs, work instructions, batch records → CERs, CSRs, and MDR/MDD documentation → Clinical protocols, study reports, and investigator brochures → Scientific and grant writing, editing, and submission-ready review Seeking for writing support that speaks the language of regulators and researchers alike? Send us a message to get started. You can also visit our website to explore all our technical capabilities. Link in the comments. #iPharmGxP #LifeSciences #MedicalWriting #TechnicalWriting #RegulatoryAffairs #ClinicalResearch

Long-term data is strengthening confidence in ELEVIDYS, Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD). In a 5-year safety analysis presented by Sarepta Therapeutics, the gene therapy ELEVIDYS (delandistrogene moxeparvovec-rokl) demonstrated a manageable safety profile across multiple clinical studies. The update consolidates data from four trials and follows the FDA’s accelerated approval of ELEVIDYS in 2023 for ambulatory DMD patients aged 4–5. DMD is a rare, progressive genetic disorder marked by muscle degeneration and currently has limited treatment options. Sarepta is working toward full approval and expanding ELEVIDYS to broader patient groups, including non-ambulatory individuals and older age cohorts. What impact do you think long-term safety data like this will have on gene therapy adoption? Share your thoughts in the comments. ————————— Read more about this development in the comments! #iPharmGxP #GeneTherapy